Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adintrevimab - Invivyd

Next Previous
X
Search
Drug Profile

Adintrevimab - Invivyd

Alternative Names: ADG-20

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adagio Therapeutics
  • Developer Invivyd
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus attachment inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in USA (IV)
  • 22 Nov 2022 Invivyd terminates a phase-II/III STAMP trial as the safety data gathered to date, it has been determined that continued participation by study subjects would not yield any additional beneficial safety information in COVID-2019 infections (In adolescents, In children, In adults, In the elderly) in Argentina, Brazil, Bulgaria, Germany, Greece, Hungary, Moldova, Poland, Romania, South Africa and Ukraine (IM) (EudraCT2020-006082-11) (NCT04805671)
  • 22 Nov 2022 Invivyd terminates a phase-II/III EVADE trial as the safety data gathered to date, it has been determined that continued participation by study subjects would not yield any additional beneficial safety information in COVID-2019 infections (In adolescents, Prevention, In adults) in USA, Argentina, Bulgaria, Czech Republic, Georgia, Germany, Moldova, Poland, Romania and Ukraine (IM) (NCT04859517)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top